Navigation Links
Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation
Date:3/13/2013

BETHESDA, Md., March 13, 2013 /PRNewswire-USNewswire/ -- The American Gastroenterological Association (AGA) Research Foundation is pleased to welcome Salix Pharmaceuticals as a supporter of the foundation's endowment.

The AGA Research Foundation provides research funding grants to young investigators in gastroenterology and hepatology.  The foundation's grants transform young researchers' lives by encouraging them to embark on and continue careers in research. Many ultimately make discoveries that improve patient care.

Salix Pharmaceuticals is a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders. 

"AGA is committed to helping young scientists investigate the GI and liver diseases that plague millions of people. AGA-funded researchers hold the keys to the patient care advances of tomorrow. AGA is thrilled that Salix recognizes the importance of supporting discovery and has made a significant commitment to the AGA Research Foundation for years to come," said Nicholas F. LaRusso , MD, AGAF, chair of the AGA Research Foundation.

Salix Pharmaceuticals' $1.125 million, five-year commitment to the AGA Research Foundation endowment will help ensure that researchers have the tools they need to discover ways to better diagnose, treat and cure digestive diseases.

"Salix is passionate about providing solutions to address unmet treatment needs for people with GI disorders," said Carolyn Logan , president and chief executive officer, Salix Pharmaceuticals.  "We are pleased to support the AGA Research Foundation in its mission of the advancement of gastroenterological and hepatological research."

Many breakthroughs have been achieved through gastroenterological and hepatological research over the past century, forming the basis of the modern medical practice. The AGA Research Foundation is working to continue this tradition of discovery and ultimately improve the lives of patients with digestive diseases through the researchers it funds. Salix's support of the AGA Research Foundation's mission is a critical investment in the future of the field of gastroenterology.

About the AGA Research Foundation
The AGA Research Foundation is the foundation of the American Gastroenterological Association (AGA), the leading professional society representing gastroenterologists and hepatologists worldwide. The mission of the foundation is to raise funds to support young researchers in gastroenterology and hepatology. The AGA Research Foundation awards nearly $1.2 million in research grants annually. www.gastro.org/foundation

About Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP®  (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO® (mesalamine) extended-release capsules 0.375 g, GIAZO™ (balsalazide disodium) tablets, COLAZAL® (balsalazide disodium) Capsule, METOZOLV® ODT (metoclopramide HCl), RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, FULYZAQ™ (crofelemer) delayed-release tablets, SOLESTA®, DEFLUX®, PEPCID® (famotidine) for Oral Suspension, DIURIL® (Chlorothiazide) Oral Suspension, AZASAN® (Azathioprine) Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, RELISTOR® , LUMACAN™ and rifaximin for additional indications are under development.

For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP, AZASAN and METOZOLV, please visit www.salix.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP".

For more information, please visit our Website at www.salix.com or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our SEC filings.

Many breakthroughs have been achieved through gastroenterological and hepatological research over the past century, forming the basis of the modern medical practice. The AGA Research Foundation is working to continue this tradition of discovery and ultimately improve the lives of patients with digestive diseases through the researchers it funds. Salix's support of the AGA Research Foundation's mission is a critical investment in the future of the field of gastroenterology.


'/>"/>
SOURCE American Gastroenterological Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
2. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
3. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
4. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
5. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
6. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
7. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
8. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
9. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
(Date:4/27/2016)... , April 27, 2016 ... over USD 2.14 billion by 2022, according to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... advancement affecting the efficiency and accuracy delivered by ... persistent demand for novel urinalysis instruments and consumables. ...
(Date:4/26/2016)... CHICAGO , April 26, 2016 Hill-Rom Holdings, ... to a management presentation at the Deutsche Bank 41 st ... at 2:50 p.m. EDT. You are invited to ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas ... one hour after conclusion of the live event and accessible ...
Breaking Medicine Technology:
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... Standards Consortium (CDISC) announces today the open availability of a new CDISC ... and catalogs for registering clinical trials. This innovative standard will make it ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, contamination ... mortality. This is particularly true in underdeveloped parts of Africa where clean sources of ... England’s campus in Tangier, Morocco, will examine this global health issue and consider how ...
(Date:4/28/2016)... ... 28, 2016 , ... One way to ignore solid evidence is to dismiss ... we toss the baby out with the bathwater when we ignore all studies because ... studies and otherwise making better use of education policy research. , “When readers heed ...
(Date:4/28/2016)... ... 28, 2016 , ... Point Source Audio® (PSA) , ... announced today that the US Patent Office has approved its patent submission that ... innovative design creates a lightweight and modular audio headset that has been said ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... containerization, today announced it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, ... , Held at Hilton Union Square, this will be MobileIron’s 6th Mobile First ...
Breaking Medicine News(10 mins):